Treatment of Measles

Introduction to Measles Treatment

• The American Academy of Pediatrics recommends measles treatment is primarily supportive care with mandatory vitamin A supplementation for all children, as there is no specific antiviral therapy available 1

Vitamin A Supplementation

• The World Health Organization recommends all children with clinical measles must receive vitamin A supplementation on day 1, with children ≥12 months receiving 200,000 IU orally and children <12 months receiving 100,000 IU orally 1, 2
• For complicated measles, a second identical dose of vitamin A should be administered on day 2 1, 2
• The Centers for Disease Control and Prevention recommends an additional dose of vitamin A 1-4 weeks later for vitamin A deficiency with eye symptoms 2

Management of Complications

• The American Academy of Pediatrics recommends treating secondary bacterial infections aggressively with appropriate antibiotics, including standard antibiotic treatment for pneumonia, appropriate antibiotic therapy for otitis media, and oral rehydration therapy for diarrhea 1, 2
• The World Health Organization recommends monitoring nutritional status and enrolling in feeding programs if indicated 1
• Diarrhea is the most frequent complication, followed by otitis media and bronchopneumonia, with encephalitis occurring in approximately 1 per 1,000 cases 2, 3

Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention recommends immune globulin (IG) 0.25 mL/kg body weight (maximum 15 mL) as soon as possible after exposure for persons with contraindications to measles vaccination requiring immediate protection 1
• For immunocompromised persons, 0.5 mL/kg body weight (maximum 15 mL) of IG is recommended 1, 4
• Measles vaccine may provide protection if administered within 72 hours of exposure 2

Diagnostic Confirmation

• The American Academy of Pediatrics recommends obtaining laboratory confirmation during the first clinical encounter, including serum measles IgM antibody testing during the first visit 1
• If negative within 72 hours of rash onset, another specimen should be obtained at least 72 hours after rash onset 1

Infection Control in Healthcare Settings

• The Centers for Disease Control and Prevention recommends implementing strict airborne precautions immediately, including airborne-infection isolation rooms and N95 respirators mandatory for all healthcare personnel regardless of immunity status 4
• The infectious period is 4 days before rash onset through 4 days after rash onset, and exposed workers without immunity must be excluded from work days 5-21 following exposure 4

Treatment of Measles

Supportive Care and Complication Management

• The Centers for Disease Control and Prevention recommends that patients with croup receive a second identical dose of vitamin A on day 2, as part of the standard protocol for complicated measles 5

Special Populations Requiring Enhanced Management

• The Centers for Disease Control and Prevention recommends that pregnant women who have been exposed to measles but are not yet symptomatic receive immune globulin (IG) 0.25 mL/kg (maximum 15 mL) within 6 days of exposure, and once symptomatic, provide supportive care with vitamin A supplementation 5

Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention recommends that MMR vaccine be administered within 72 hours of exposure to provide protection or modify disease severity, and for susceptible household contacts who cannot receive vaccine, standard dose IG 0.25 mL/kg (maximum 15 mL) within 6 days of exposure 6
• The Centers for Disease Control and Prevention recommends that for susceptible household contacts who cannot receive vaccine, immunocompromised individuals receive IG 0.5 mL/kg (maximum 15 mL) within 6 days of exposure 7

Post‑Exposure Prophylaxis and Complication Rates in Measles

Complication Incidence

Post‑Exposure Prophylaxis with Immune Globulin

Indications

Dosing Recommendations

MMR Vaccine as Alternative Prophylaxis

Clinical Pitfalls

Measles Treatment Guidelines (CDC MMWR Recommendations)

Vitamin A Supplementation

• Standard single‑dose regimen: For patients ≥ 12 months (including adults) give 200,000 IU oral vitamin A on day 1; for patients < 12 months give 100,000 IU oral vitamin A on day 1, provided they have not received vitamin A in the preceding month. Strong recommendation based on high‑quality evidence. 10

• Enhanced two‑dose regimen for complicated measles: Administer an identical second dose on day 2 when any of the following complications are present – pneumonia, otitis media, croup, diarrhea with moderate or severe dehydration, or neurological problems. Strong recommendation; evidence shows a 64 % reduction in overall mortality (RR 0.36) and a 67 % reduction in pneumonia‑specific mortality (RR 0.33), with an 82 % mortality reduction in children < 2 years (RR 0.18). 10

• Extended protocol for vitamin A‑deficiency eye manifestations: When eye signs such as xerosis, Bitot’s spots, keratomalacia, or corneal ulceration are observed, give 200,000 IU on day 1, another 200,000 IU on day 2, and a third 200,000 IU dose 1–4 weeks later; infants < 12 months receive half these doses (100,000 IU). Strong recommendation. 10

Supportive Care

• Management of secondary bacterial pneumonia or acute lower‑respiratory infection: Initiate standard antibiotic therapy as per local protocols. Strong recommendation. 10

• Treatment of otitis media: Provide appropriate antibiotic therapy when indicated. Strong recommendation. 10

• Management of diarrhoea: Use oral rehydration therapy (ORT) promptly. Strong recommendation. 10

• Nutritional monitoring: Assess and monitor the nutritional status of every measles patient; enroll in supplemental feeding programs in resource‑limited settings when needed. Strong recommendation. 10

• Antipyretic use: Administer antipyretics (e.g., acetaminophen or ibuprofen) as required for fever control, following general pediatric practice. Moderate recommendation. 11

Post‑Exposure Prophylaxis (PEP)

• MMR vaccine for susceptible contacts: Offer a dose of measles‑mumps‑rubella vaccine within 72 hours of exposure; this can prevent infection or attenuate disease severity. Strong recommendation. 12

Isolation and Infection‑Control Considerations in Resource‑Limited Settings

• Airborne isolation in standard healthcare facilities: Implement airborne‑infection isolation rooms and require all healthcare personnel to wear N95 respirators, regardless of presumed immunity. Strong recommendation. (Citation derived from CDC MMWR; see 10 and 11 for related guidance.)

• Exception for emergency refugee‑camp settings: In outbreak situations where isolation resources are unavailable, prioritize mass vaccination over isolation; airborne isolation is not required in such contexts. Strong recommendation. [10][11]

Measles Infection Control and Post‑Exposure Prophylaxis

Infection‑Control Measures

• Staff entering a measles isolation room should wear N95 respirators (or equivalent) and the patient should be placed in a negative‑pressure or private closed‑door room. [CDC, MMWR Recommendations and Reports 2011] 13

Healthcare‑Personnel Exclusion

• Healthcare workers without documented measles immunity must be excluded from work from day 5 through day 21 after exposure. [CDC, MMWR Recommendations and Reports 2011] 13
• If a exposed worker develops measles, they must remain excluded until at least 4 days after rash onset. [CDC, MMWR Recommendations and Reports 2011] 13

Post‑Exposure Vaccination

• Administer a single dose of MMR vaccine within 72 hours of measles exposure to susceptible contacts aged ≥ 6 months (excluding pregnant persons, immunocompromised individuals, and those with vaccine contraindications). [CDC, MMWR Recommendations and Reports 1998] 14

Immunoglobulin (IG) Prophylaxis

• For general susceptible contacts, give intramuscular IG at 0.25 mL/kg (maximum 15 mL) within 6 days of exposure. [CDC, MMWR Recommendations and Reports 1998] 14
• For immunocompromised susceptible contacts, give intramuscular IG at 0.5 mL/kg (maximum 15 mL) within 6 days of exposure. [CDC, MMWR Recommendations and Reports 1998] 14

Measles Management: Clinical Assessment and Supportive Care

Assessment of Respiratory Distress

• Markedly raised respiratory rate, grunting, intercostal recession, breathlessness with chest signs, or cyanosis are the key clinical signs used to identify respiratory distress in children with measles. 15

Hospital Admission Criteria

• The appearance of any danger sign—including respiratory distress (as defined above), cyanosis, severe dehydration, altered level of consciousness, or signs of septicemia (extreme pallor, hypotension, floppy infant)—requires immediate referral for hospital assessment in measles patients. 15, 16

Antipyretic Therapy (Supportive Care)

• Fever should be managed with acetaminophen or ibuprofen; aspirin is contraindicated in children younger than 16 years. 15

Fluid Management (Supportive Care)

• Adequate hydration, preferably with oral rehydration therapy, must be provided to maintain fluid balance in measles patients who have diarrhea. 15

Routine Vitamin A Follow‑Up Supplementation after Acute Measles Treatment

Follow‑Up Schedule for At‑Risk Populations

• In communities with a high prevalence of vitamin A deficiency, children should receive additional oral vitamin A supplementation every 3 months after they have completed the standard acute measles treatment regimen (day 1 and day 2 doses). This recommendation is issued by the CDC (MMWR Recommendations and Reports). 17